Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Phase 4 N=694 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
Essential Hypertension
Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 4 N=24 Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
Hypertension
Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…
N/A N=343 Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy
Hypertension, Pregnancy-Induced · Postpartum Preeclampsia · Hypertension; Maternal
Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants
Phase 4 N=2,408 Chronic Hypertension and Pregnancy (CHAP) Project
Hypertension
Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001
Phase 3 N=2,204 Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Essential Hypertension
Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
N/A N=574 Targeting of UnControlled Hypertension in Emergency Department
Hypertension · Cardiovascular Diseases · Vascular Diseases
Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 4 N=412 Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 167.08; 167.41; 130.73; 137.87 mmHg
N/A N=146 The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department
Hypertension · Emergencies · Asymptomatic Conditions
Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants
N/A N=125 Self-Management and Resilience Trajectories in African American Adults With Hypertension
Hypertension · Self-Management · Quality of Life
Primary: Systolic Blood Pressure — 138.35; 135.56 mmHg — p=0.0050
Phase 3 N=2,244 Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Hypertension
Primary: Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 — -4.0; 1.4; -1.5; 0.4 mmHg — p=<.0001
Phase 4 N=860 Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
Hypertension · Diabetes Mellitus
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
Phase 4 N=488 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
N/A N=200 Perioperative Blood Pressures and Chronic Hypertension
Hypertension
Primary: Performance of Blood Pressure Referral Threshold — .841 proportion
Phase 3 N=1,010 Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648
Phase 4 N=664 Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
Stage 2 Diastolic Hypertension
Primary: The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6. — -8.0; -17.2; -13.3; -12.0 mm HG
N/A N=591 Hypertension Intervention Nurse Telemedicine Study (HINTS)
Hypertension
Primary: Estimated Percentage of Participants in Blood Pressure Control at Baseline — 61; 59; 53; 64 % of particpants w/ controlled BP
Phase 3 N=971 Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001
Phase 4 N=105 Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
Hypertension
Primary: The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 — 34.0; 59.2 Percent of participants — p=0.0158
Phase 4 N=532 Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
Hypertension
Primary: Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP) — -30.38; -20.15 mm Hg
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
Phase 3 N=932 Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
Essential Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg
Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
N/A N=17 Controlling and Lowering Blood Pressure With The MOBIUSHD™
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
Phase 2 N=250 Treatment of Early Hypertension Among Persons Living With HIV in Haiti
HIV/AIDS · Pre Hypertension
Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001